Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01682083
Registration number
NCT01682083
Ethics application status
Date submitted
6/09/2012
Date registered
10/09/2012
Titles & IDs
Public title
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
Query!
Scientific title
COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection
Query!
Secondary ID [1]
0
0
2012-001266-15
Query!
Secondary ID [2]
0
0
115532
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
COMBI-AD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dabrafenib
Treatment: Drugs - Trametinib
Treatment: Drugs - Placebos
Experimental: Dabrafenib and trametinib - Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
Placebo comparator: Dabrafenib and trametinib placebos - Subjects received matching placebos orally for 12 months
Treatment: Drugs: Dabrafenib
Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)
Treatment: Drugs: Trametinib
Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
Treatment: Drugs: Placebos
The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Relapse-free Survival (RFS)
Query!
Assessment method [1]
0
0
Recurrence-free survival was defined as the time from randomization to disease recurrence (local recurrence, distant recurrence, second primary melanoma), or death from any cause.
Query!
Timepoint [1]
0
0
Approximately 3.5 years
Query!
Secondary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Overall survival (OS) of dabrafenib and trametinib as a combination therapy versus placebo
Query!
Timepoint [1]
0
0
approximately 3.5 years
Query!
Secondary outcome [2]
0
0
Distant Metastasis-free Survival
Query!
Assessment method [2]
0
0
Distant metastasis-free survival (DMFS) of dabrafenib and trametinib as a combination therapy versus placebo. In the DMFS analysis, the first occurrence of distant metastasis or death (if it occurred before documented recurrence) was counted as an event.
Query!
Timepoint [2]
0
0
approximately 3.5 years
Query!
Secondary outcome [3]
0
0
Freedom From Relapse
Query!
Assessment method [3]
0
0
Freedom from relapse (FFR) of dabrafenib and trametinib as a combination therapy versus placebo. In the FFR analysis, local or distant recurrence or a new primary melanoma were counted as events, and patients who died of causes other than melanoma or treatment-related toxicity were censored.
Query!
Timepoint [3]
0
0
approximately 3.5 years
Query!
Eligibility
Key inclusion criteria
Key
* Completely resected histologically confirmed high-risk [Stage IIIa (LN metastasis more than 1 mm), IIIb or IIIc cutaneous melanoma determined to be V600E/K mutation positive by a central laboratory. Patients presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible.
* Surgically rendered free of disease no more than 12 weeks before randomization.
* Recovered from definitive surgery (e.g. no uncontrolled wound infections or indwelling drains).
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
* Adequate hematologic, hepatic, renal and cardiac function.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Known mucosal or ocular melanoma or the presence of unresectable in-transit metastases.
* Evidence of distant metastatic disease.
* Prior systemic anti-cancer treatment and radiotherapy for melanoma; prior surgery for melanoma is allowed.
* History of another malignancy or concurrent malignancy including prior malignant melanoma. Exceptions to this include: Patients who have been disease-free for 5 years or patients with a history completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ, multiple primary melanomas, or other malignancies for which the patient has been disease free for > 5 years.
* History or current evidence of cardiovascular risk.
* History or current evidence of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/01/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
31/07/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
870
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Gateshead
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - North Sydney
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Tweed Heads
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - Westmead
Query!
Recruitment hospital [5]
0
0
Novartis Investigative Site - Greenslopes
Query!
Recruitment hospital [6]
0
0
Novartis Investigative Site - Milton
Query!
Recruitment hospital [7]
0
0
Novartis Investigative Site - Woolloongabba
Query!
Recruitment hospital [8]
0
0
Novartis Investigative Site - Adelaide
Query!
Recruitment hospital [9]
0
0
Novartis Investigative Site - Box Hill
Query!
Recruitment hospital [10]
0
0
Novartis Investigative Site - Heidelberg
Query!
Recruitment hospital [11]
0
0
Novartis Investigative Site - Melbourne
Query!
Recruitment hospital [12]
0
0
Novartis Investigative Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2290 - Gateshead
Query!
Recruitment postcode(s) [2]
0
0
2060 - North Sydney
Query!
Recruitment postcode(s) [3]
0
0
2485 - Tweed Heads
Query!
Recruitment postcode(s) [4]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [5]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [6]
0
0
4064 - Milton
Query!
Recruitment postcode(s) [7]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [8]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [9]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [10]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [11]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [12]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Jersey
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oregon
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Tennessee
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Utah
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Washington
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Buenos Aires
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Río Negro
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Santa Fe
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Ciudad Autonoma de Buenos Aires
Query!
Country [25]
0
0
Austria
Query!
State/province [25]
0
0
Graz
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Innsbruck
Query!
Country [27]
0
0
Austria
Query!
State/province [27]
0
0
Linz
Query!
Country [28]
0
0
Austria
Query!
State/province [28]
0
0
Salzburg
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Wels
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Wien
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Brussels
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Leuven
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Liege
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Wilrijk
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Goiás
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Paraná
Query!
Country [37]
0
0
Brazil
Query!
State/province [37]
0
0
Rio Grande Do Sul
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
Rio De Janeiro
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
São Paulo
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Alberta
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Ontario
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Quebec
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Brno
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Hradec Kralove
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Olomouc
Query!
Country [46]
0
0
Czechia
Query!
State/province [46]
0
0
Praha 10
Query!
Country [47]
0
0
Czechia
Query!
State/province [47]
0
0
Praha 2
Query!
Country [48]
0
0
Czechia
Query!
State/province [48]
0
0
Zlin
Query!
Country [49]
0
0
Denmark
Query!
State/province [49]
0
0
Arhus C
Query!
Country [50]
0
0
Denmark
Query!
State/province [50]
0
0
Herlev
Query!
Country [51]
0
0
Denmark
Query!
State/province [51]
0
0
Odense
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Bordeaux
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Boulogne-Billancourt
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Brest cedex
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Dijon
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Grenoble
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Lille
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Marseille cedex 5
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Montpellier cedex 5
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Nice
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Paris Cedex 10
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Paris
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Pierre-Benite cedex
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Reims Cedex
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Rennes Cedex
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Toulouse cedex 9
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Tours Cedex 9
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Villejuif cedex
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Baden-Wuerttemberg
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Bayern
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Hessen
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Mecklenburg-Vorpommern
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Niedersachsen
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Nordrhein-Westfalen
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Rheinland-Pfalz
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Saarland
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Sachsen-Anhalt
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Schleswig-Holstein
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Thueringen
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Berlin
Query!
Country [81]
0
0
Greece
Query!
State/province [81]
0
0
Athens
Query!
Country [82]
0
0
Greece
Query!
State/province [82]
0
0
Thessaloniki
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Jerusalem
Query!
Country [84]
0
0
Israel
Query!
State/province [84]
0
0
Ramat Gan
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
Lazio
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Liguria
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Lombardia
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Piemonte
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Toscana
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Veneto
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Shizuoka
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Tokyo
Query!
Country [93]
0
0
Netherlands
Query!
State/province [93]
0
0
Amsterdam
Query!
Country [94]
0
0
Netherlands
Query!
State/province [94]
0
0
Groningen
Query!
Country [95]
0
0
Netherlands
Query!
State/province [95]
0
0
Leeuwarden
Query!
Country [96]
0
0
Netherlands
Query!
State/province [96]
0
0
Maastricht
Query!
Country [97]
0
0
Netherlands
Query!
State/province [97]
0
0
Nijmegen
Query!
Country [98]
0
0
Netherlands
Query!
State/province [98]
0
0
Rotterdam
Query!
Country [99]
0
0
New Zealand
Query!
State/province [99]
0
0
Auckland
Query!
Country [100]
0
0
Norway
Query!
State/province [100]
0
0
Alesund
Query!
Country [101]
0
0
Norway
Query!
State/province [101]
0
0
Oslo
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Gdansk
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Konin
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Poznan
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Warszawa
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
Chelyabinsk
Query!
Country [107]
0
0
Russian Federation
Query!
State/province [107]
0
0
Moscow
Query!
Country [108]
0
0
Russian Federation
Query!
State/province [108]
0
0
Ryazan
Query!
Country [109]
0
0
Russian Federation
Query!
State/province [109]
0
0
St. Petersburg
Query!
Country [110]
0
0
Russian Federation
Query!
State/province [110]
0
0
Volgograd
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Badalona
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Barcelona
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Cartagena
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Las Palmas De Gran Canaria
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Madrid
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Malaga
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Palma de Mallorca
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Pamplona
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
San Sebastian
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Santander
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Sevilla
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Valencia
Query!
Country [123]
0
0
Sweden
Query!
State/province [123]
0
0
Goteborg
Query!
Country [124]
0
0
Sweden
Query!
State/province [124]
0
0
Lund
Query!
Country [125]
0
0
Sweden
Query!
State/province [125]
0
0
Stockholm
Query!
Country [126]
0
0
Sweden
Query!
State/province [126]
0
0
Uppsala
Query!
Country [127]
0
0
Switzerland
Query!
State/province [127]
0
0
Basel
Query!
Country [128]
0
0
Switzerland
Query!
State/province [128]
0
0
Chur
Query!
Country [129]
0
0
Switzerland
Query!
State/province [129]
0
0
Zurich
Query!
Country [130]
0
0
Taiwan
Query!
State/province [130]
0
0
Taichung
Query!
Country [131]
0
0
Taiwan
Query!
State/province [131]
0
0
Taipei
Query!
Country [132]
0
0
Taiwan
Query!
State/province [132]
0
0
Taoyuan
Query!
Country [133]
0
0
United Kingdom
Query!
State/province [133]
0
0
Middlesex
Query!
Country [134]
0
0
United Kingdom
Query!
State/province [134]
0
0
Exeter
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
Glasgow
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Guildford
Query!
Country [137]
0
0
United Kingdom
Query!
State/province [137]
0
0
Leeds
Query!
Country [138]
0
0
United Kingdom
Query!
State/province [138]
0
0
London
Query!
Country [139]
0
0
United Kingdom
Query!
State/province [139]
0
0
Manchester
Query!
Country [140]
0
0
United Kingdom
Query!
State/province [140]
0
0
Newcastle upon Tyne
Query!
Country [141]
0
0
United Kingdom
Query!
State/province [141]
0
0
Norwich
Query!
Country [142]
0
0
United Kingdom
Query!
State/province [142]
0
0
Preston
Query!
Country [143]
0
0
United Kingdom
Query!
State/province [143]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus two placebos in the adjuvant treatment of melanoma after surgical resection. Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk \[Stage IIIa (lymph node metastasis \>1 mm), IIIb or IIIc\] cutaneous melanoma were screened for eligibility. Subjects were randomized to receive either dabrafenib (150 milligram (mg) twice daily \[BID\]) and trametinib (2 mg once daily \[QD\]) combination therapy or two placebos for 12 months.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01682083
Query!
Trial related presentations / publications
Schadendorf D, Robert C, Dummer R, Flaherty KT, Tawbi HA, Menzies AM, Banerjee H, Lau M, Long GV. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. Eur J Cancer. 2021 Aug;153:234-241. doi: 10.1016/j.ejca.2021.05.005. Epub 2021 Jul 2. Dummer R, Hauschild A, Santinami M, Atkinson V, Mandala M, Kirkwood JM, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 Sep 17;383(12):1139-1148. doi: 10.1056/NEJMoa2005493. Epub 2020 Sep 2. Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, Long GV. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 Mar;21(3):358-372. doi: 10.1016/S1470-2045(20)30062-0. Epub 2020 Jan 30. Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27. Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018 Dec 10;36(35):3441-3449. doi: 10.1200/JCO.18.01219. Epub 2018 Oct 22. Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/83/NCT01682083/Prot_001.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/83/NCT01682083/SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01682083